fda reconsiders tirzepatide FDA's Weight Loss Drug 'No Man's Land' Adds Risk for Compounders Tirzepatide Update: On December 19th

DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020

Identifying additional benefits could help us understand the biological pathways influenced by these drugs and uncover new opportunities for disease prevention and treatment, including cancer prevention. Aparna Kamat, MD Kamat is the senior author of a new study published in the journal Annals of Oncology that found a potential link between taking GLP-1 medications, such as Ozempic , Wegovy , Zepbound , and Mounjaro , and a decrease in the overall risk of developing obesity-related cancers in people without diabetes

Eating behavior modifications are equally important

While encouraging for basic safety, a two-person pilot study without a control group provides very limited evidence